Changes in US stocks | WVE-007 phase 1 trial showed positive results Wave Life Sciences (WVE.US) opened and soared nearly 80%

The Zhitong Finance App learned that on Monday, Wave Life Sciences (WVE.US) surged nearly 80% to a new high of $13.42 during the year. According to the news, the company said that interim data from its WVE-007 phase 1 trial to treat obesity showed improvements in body composition. At the lowest treatment dose, the weight loss effect was similar to GLP-1, but there was no muscle loss.

Studies have shown that a single 240 mg dose of WVE-007 can reduce visceral fat by 9.4%, reduce body fat by 4.5%, and increase lean body weight by 3.2%. Wave Life Sciences also said that interim data further showed that WVE-007 was generally safe and well tolerated, with only minor treatment-related adverse events. Further clinical data updates are expected to be released in the first quarter of 2026, including six-month follow-up data for the 240 mg single dose group.